Carphedon at the Crossroads: A Dangerous Drug or a Promising Psychopharmaceutical?

Jiri Patocka
Additional contact information
Jiri Patocka: Faculty of Health and Social Studies, University of South Bohemia České Budějovice, Czech Republic

Global Journal of Pharmacy & Pharmaceutical Sciences, 2019, vol. 7, issue 3, 83-87

Abstract: Carphedon is a phenyl derivative of the nootropic drug piracetam (Nootropil) and is effective in increasing physical endurance and cold resistance and is used for amnesia treatment. It was developed in Russia as a stimulant to keep astronauts awake on long missions, and occasionally used in Russia as a nootropic prescription for various types of neurological disease. It became well known a couple years ago when a leading nootropic supplier in California started selling it on the Internet as a supplement and a bunch of athletes got kicked out of the Olympics for illegal using it. Carphedon was found to activate the operant behavior more powerfully, to remove psychodepressant effects of diazepam, to inhibit post-rotational nystagmus, and to prevent the development of retrograde amnesia. Unlike piracetam, carphedon exhibits a specific anticonvulsant action. When given in high doses, produces psychodepressant effects. It is also claimed to increase physical stamina and provide improved tolerance to cold. As a result, it appears on the lists of banned substances issued by the World Anti-Doping Agency.

Keywords: juniper publishers:Journal of Pharmacy; Global Journal of Pharmacy; Pharmaceutical Sciences; Pharmacy & Pharmaceutical Sciences; pharmaceutical sciences journals; omics online; open access; drug discovery; Clinical Trials; juniper publishers open access journals; juniper publishers reivew (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/gjpps/pdf/GJPPS.MS.ID.555713.pdf (application/pdf)
https://juniperpublishers.com/gjpps/GJPPS.MS.ID.555713.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jgjpps:v:7:y:2019:i:3:p:83-87

DOI: 10.19080/GJPPS.2019.07.555713

Access Statistics for this article

Global Journal of Pharmacy & Pharmaceutical Sciences is currently edited by Sophia Mathis

More articles in Global Journal of Pharmacy & Pharmaceutical Sciences from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().